Publications by authors named "Ilana Segal"
Article Synopsis
- Researchers developed a new small molecule antiviral called PAV-431 that was discovered through a unique screening method targeting viral protein assembly.
- This compound has shown effectiveness against various respiratory viruses in laboratory studies and in animal models, including coronaviruses and paramyxoviruses.
- PAV-431 works by selectively targeting a modified protein complex involved in the viral life cycle, providing a potential new approach for treating respiratory viral infections without harming the host.
Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) possess mutations that prevent antibody therapeutics from maintaining antiviral binding and neutralizing efficacy. Monoclonal antibodies (mAbs) shown to neutralize Wuhan-Hu-1 SARS-CoV-2 (ancestral) strain have reduced potency against newer variants. Plasma-derived polyclonal hyperimmune drugs have improved neutralization breadth compared with mAbs, but lower titers against SARS-CoV-2 require higher dosages for treatment.
View Article and Find Full Text PDFWe present a novel small molecule antiviral chemotype that was identified by an unconventional cell-free protein synthesis and assembly-based phenotypic screen for modulation of viral capsid assembly. Activity of PAV-431, a representative compound from the series, has been validated against infectious virus in multiple cell culture models for all six families of viruses causing most respiratory disease in humans. In animals this chemotype has been demonstrated efficacious for Porcine Epidemic Diarrhea Virus (a coronavirus) and Respiratory Syncytial Virus (a paramyxovirus).
View Article and Find Full Text PDFObjective: Exploration of the possibility that local injury of the endometrium increases the incidence of implantation.
Design: Prospective study.
Setting: Clinical IVF unit.